Hospital pharmacists and members of the multidisciplinary team – such as nurses, pharmacy technicians and others – are dealing with hazardous medicinal products in their daily work. Their safe handling is of uttermost importance for the safety of healthcare workers and patients treated with these medicines. Their classification plays an essential role in determining suitable handling procedures. However, unlike the United States, Europe does not have one single body similar to the National Institute for Occupational Safety and Health (NIOSH) that addresses all questions linked to the classification of hazardous medicinal products.
 
To better understand the classification landscape for hazardous medicinal products in Europe, the European Association of Hospital Pharmacists (EAHP) has established a Special Interest Group (SIG) on Hazardous Medicinal Products which is seeking further input for their work by means of this survey.
 
We thank all chief pharmacists for participating in the EAHP Survey on Hazardous Medicinal Products.
 
It takes approximately 20 to 25 minutes to complete the survey.
 
This survey will be closed on the 10th of October 2021.
 

In the absence of a European definition of the term ‘hazardous medicinal product’, EAHP’s SIG reserves the right to propose a definition arising from the work of the group.
 
 
The definition of the term ‘hazardous medicinal product (HMP)’ used throughout this survey is a modification of the definition used by NIOSH chosen because of its familiarity:
 
Drugs are classified as hazardous when they possess any one of the following five characteristics regardless of the proposed formulation and recommended route of administration
  • Genotoxicity, or the ability to cause a change or mutation in genetic material; a mutagen. 
  • Carcinogenicity, or the ability to cause cancer in humans, animal models, or both; a carcinogen.
  • Teratogenicity, or developmental toxicity, the ability to interfere with normal development, either before or after birth. 
  • Fertility impairment. 
  • Serious organ toxicity at low doses in humans or animal models. 
 
Note: This also covers medicines that should not be crushed but are crushed by a healthcare worker in a home setting.

0 of 36 answered
 

T